Novartis gene therapy would be cost effective up to $900,000: U.S. group
An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Novartis gene therapy would be cost effective up to $900,000: U.S. group
An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would be worth a price of $310,000 to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Novartis gene therapy is cost effective at up to $900,000: U.S. group
An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would offer value at a price of $310,000 to $900,000, according an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Wheelchair-bound girl struggles to pour herself a drink because of rare muscle weakening condition
Sophie Anderson has the genetic Spinal Muscular Atrophy Type Two (SMA). She has been in a wheelchair since she was diagnosed at 12 months old. (Source: the Mail online | Health)
Source: the Mail online | Health - January 21, 2019 Category: Consumer Health News Source Type: news
U.S Body Says Gene Therapy May Be More Cost Effective for Spinal Muscular Atrophy U.S Body Says Gene Therapy May Be More Cost Effective for Spinal Muscular Atrophy
Biogen Inc ' s Spinraza (nusinersen) treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG ' s experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 24, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
